Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease
| Autor: | Vera Nevzorova, Zaurbek Aisanov, Svetlana Ovcharenko, Juliya V. Zhernakova, Tat’iana A. Brodskaia, Irina Chazova, A. G. Chuchalin, Lali G. Ambatiello, Andrei S. Belevskii, Elena V. Oshchepkova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
arterial hypertension Combination therapy medicine.drug_class 030204 cardiovascular system & hematology chronic obstructive pulmonary disease treatment of arterial hypertension and chronic obstructive pulmonary disease combination 03 medical and health sciences 0302 clinical medicine Internal medicine Bronchodilator comorbid pathology medicine Diseases of the circulatory (Cardiovascular) system Roflumilast Thiazide COPD business.industry Tiotropium bromide medicine.disease respiratory tract diseases Blood pressure 030228 respiratory system RC666-701 recommendations Formoterol business medicine.drug |
| Zdroj: | Системные гипертензии, Vol 17, Iss 3, Pp 7-34 (2020) |
| ISSN: | 2542-2189 |
| Popis: | One of the most common comorbid condition in people over 40 years old is: arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD). The frequency of AH in patients with COPD varies from 6.8 to 76.3%, in average 34.3%. COPD is detected in every fourth patient with hypertension in the age group of 2564 years. The current trend towards an increase in life expectancy and therefore growing pool of elder cohort, will lead to a higher number of patients with comorbid disorders. Diagnosis and treatment of AH and COPD are determined by current clinical recommendations for both nosologies, however, a number of mutual pathophysiological mechanisms lead to a more severe course of these diseases with frequent exacerbations. The choice of antihypertensive therapy in patients with AH in combination with COPD should be given to drugs that can provide an adequate decrease in blood pressure in hypoxic conditions, especially at night and early morning hours, that have prolonged effect or could be prescribed in the evening, and to those that dont worsen bronchial obstruction or exacerbate hypoxia. Patients with AH and COPD should be given recommendations on lifestyle changes, especially smoking cessation. As initial therapy calcium channel blockers, angiotensin receptor blockers or angiotensin-converting enzyme inhibitors should be considered. Calcium channel blockers/renin-angiotensin system blockers should be considered as the first line for combination therapy. Thiazide, thiazide-like diuretics orb1-selective adrenergic blockers could be prescribed in case of insufficient antihypertensive response or depending on different clinical scenarios. Bronchodilators are the baseline therapy in COPD with concomitant AH. According to modern concepts, prescription of combination therapy with different mechanisms of action is the most proven and justified approach, which leads to a decrease in the frequency of exacerbations of COPD and amelioration of the symptoms. The choice of bronchodilator in the case of a COPD and AH combination, should take into account the proven long-term safety regarding the risk of cardiovascular complications. Tiotropium bromide as the monotherapy, including as a liquid inhaler and aclidinium/formoterol, tiotropium/oladeterol as combination therapy showed cardiovascular safety in the long-term studies. The escalation of COPD therapy with the need of inhaled steroids requires careful monitoring of blood pressure and, possibly, a revision of antihypertensive treatment leading to its escalation as well. COPD has many phenotypes requiring different medications, eg.: roflumilast, theophylline, macrolides and mucoactive drugs, that could also require tighter blood pressure control on patients with COPD and AH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|